B. Riley Securities Reiterates Buy on Zymeworks, Raises Price Target to $44
Zymeworks Inc.
Zymeworks Inc. ZYME | 0.00 |
B. Riley Securities analyst Mayank Mamtani reiterates Zymeworks (NASDAQ:
ZYME) with a Buy and raises the price target from $40 to $44.
